zh-twzhen
zh-twzhen

Oneness Biotech Co., Ltd., has been granted the Brazil Good Manufacturing Practice (B-GMP) certification for Bonvadis from Brazil ANVISA.

2024

Date

Title

2024-05-13

The Board of Directors approved the amendment of 2023 Restricted Stock Awards Issuance Rules

>
2024-05-09

S.C. injection formulation of FB825 has been agreed by US FDA to proceed with Phase 2 clinical trial to treat moderate-to-severe atopic dermatitis.

>
2024-05-03

Announcement the Company’s board of directors meeting date of the First Quarter of 2024 Consolidated Financial Reports

>
2024-05-02

Oneness Biotech Co., Ltd. receives a Japanese patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2024-04-30

News-Microbio and Oneness Ranked among Top 5% in the 10th Corporate Governance Evaluation

>
2024-04-22

Subcutaneous injection formulation of FB825 to treat moderate-to-severe atopic dermatitis was greenlighted by TFDA to proceed with a Ph2 study

>
2024-03-29

Submission of a phase II clinical trial protocol to Taiwan FDA for subcutaneous injection formulation of FB825 in patients with moderate-to-severe atopic dermatitis

>
2024-03-22

Oneness announces the information about the investor’s conference of 2024 Q1.

>
2024-03-19

Oneness Biotech Co., Ltd. receives a Saudi Arabian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2024-02-29

The board of directors of the Company approved removal of the noncompete clause for managers.

>
2024-02-29

Annouce the change of the spokesperson.

>
2024-02-29

Annouce the change of the general manager.

>
2024-02-29

Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2024.

>
2024-02-29

The Board of Directors resolved to the new common share issuance through the increase of capital by capitalization of capital surplus

>
2024-02-29

The Board of Directors resolved to distribute dividends.

>